STOCK TITAN

Jabil and ams OSRAM Enable Innovative Lateral Flow Testing Platform

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Jabil (NYSE: JBL) has partnered with ams OSRAM to develop a lateral flow testing platform aimed at enhancing COVID-19 testing capabilities. This initiative leverages optical technology for quicker results, providing a diagnosis in approximately 15 minutes. The collaboration was expedited due to increased demand for decentralized testing, resulting in a product launch within 12 months. Jabil's extensive manufacturing capabilities and ISO certifications played a crucial role in meeting supply chain challenges. Future applications of this technology may extend to other health diagnostics and veterinary testing.

Positive
  • Successful collaboration with ams OSRAM to develop a lateral flow testing platform.
  • Product launched in under 12 months despite supply chain challenges.
  • Utilization of advanced optical technology for rapid diagnostics.
  • Potential for licensing technology to expand future applications in health diagnostics.
Negative
  • None.

In Less Than 12 Months, Jabil Helps the Optics Leader Launch Digital Testing Platform with Licensable Technology for Novel Applications

ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- Jabil (NYSE: JBL) today announced the next step in its manufacturing and supply chain collaboration with ams OSRAM, a global leader in optical solutions, with the development of a lateral flow testing platform. The COVID-19 pandemic brought the topic of testing to the forefront, validating the importance of reliable and robust lab-quality testing that can be conducted remotely and with fast turnaround times. With the role of testing only increasing in the future for infectious diseases beyond the current crisis, the teams at ams OSRAM and Jabil saw an opportunity to bring these lateral flow tests into the digital age, leveraging optics and connectivity technologies to simplify patient experience and deliver clear results in approximately 15 minutes.

“Within ams OSRAM, we had a project focused on the digitization of lateral flow testing prior to the pandemic. COVID-19 accelerated the demand for decentralized testing, and we needed a partner that could help us bring our solution to market quickly and at high volumes,” said Wim Renirie, ams OSRAM’s vice president and general manager of BL Accessory and Wearable Solutions. “With Jabil, we found a partner that could meet our high volumes and manage unpredictable demand as the situation evolved.”

When Jabil joined the project in the spring of 2020, supply chains were already constrained due to border closures, plant shutdowns and staffing reductions in logistics and manufacturing. Supply chain orchestration rapidly became a top priority, with Jabil’s supply chain managers identifying the product’s vital components and leveraging their supplier relationships to procure the necessary parts at both the required volumes and the most competitive prices.

“The path for time-to-market was very aggressive. ams OSRAM was looking to have the product in market in less than 12 months,” said Jeffrey Roberts, business unit director for Jabil Healthcare. “We were starting with a whiteboard, with a brand-new circuit board design and new manufacturing processes for this device. To achieve this in less than 12 months was one of the toughest timelines we have ever had to achieve.”

Together, ams OSRAM and Jabil designed the test’s essential component — a complete printed circuit board assembly (PCBA), manufactured by Jabil, that leverages ams OSRAM’s spectral sensing technology. An LED illuminates the lateral flow test, and a highly sensitive spectral sensor reads the color of the line, providing an objective “positive” or “negative” result. The connection module sends that result via Bluetooth to a cloud-based smartphone app that clearly states the patient’s COVID-19 status.

The ambitious timeline for securing all required regulatory clearances and getting the device to market galvanized the teams' collaboration, clarifying what each brought to the table to beat the clock and get the job done. ams OSRAM was able to rely upon Jabil's broad technical capabilities, particularly relating to diagnostics and optics technologies as well as Jabil's extensive healthcare manufacturing certifications. Also, with over 30 ISO 13485-certified medical device manufacturing sites located around the world, Jabil had the ability to support production across all time zones and in nearly every market.

The success of ams OSRAM and Jabil’s joint endeavor was about more than just successful manufacturing. The two companies are just beginning to explore the potential applications for this device beyond COVID-19, from diabetes to veterinary testing.

“The work we have completed on this technology is available for licensing by other companies looking to implement lateral flow technology and could accelerate standard development timelines by months. This is giving new life to lateral flow testing for the next 10 to 20 years because you open up a whole range of new use cases,” said Renirie.

Supporting Resources

About Jabil:

Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.

Michelle Saro

Senior Director of Marketing, Jabil

1.206.272.0813

Michelle_saro@jabil.com

Source: Jabil, Inc.

FAQ

What is Jabil's recent partnership about?

Jabil has partnered with ams OSRAM to create a lateral flow testing platform that enhances COVID-19 testing with faster and more reliable results.

How quickly did Jabil and ams OSRAM launch their testing platform?

The testing platform was developed and launched in less than 12 months.

What technology does the lateral flow testing platform use?

The platform leverages optics and connectivity technologies for rapid testing, delivering results in approximately 15 minutes.

Can the technology developed by Jabil be used for other applications?

Yes, the technology has potential applications beyond COVID-19, including diagnostics for diabetes and veterinary testing.

What role did supply chain management play in the development of the testing platform?

Jabil's supply chain managers identified vital components and leveraged supplier relationships to meet high volume demands amidst challenging conditions.

Jabil Inc.

NYSE:JBL

JBL Rankings

JBL Latest News

JBL Stock Data

16.09B
109.50M
3.12%
95.24%
2.37%
Electronic Components
Printed Circuit Boards
Link
United States of America
ST PETERSBURG